Aug 31 (Reuters) - Britain's GlaxoSmithKline and South Korea's SK Bioscience said on Tuesday the drugmakers have begun a late-stage clinical study of SK's COVID-19 vaccine candidate in combination with GSK's pandemic vaccine booster. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Shounak Dasgupta)
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
58,800 KRW | +0.17% | +2.44% | -18.33% |
03/05 | SK Bioscience's Attributable Loss Narrows in Q1 | MT |
28/03 | SK Bioscience Signs Deal with Sanofi for Five Vaccine Types | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.33% | 3.33B | |
+1.45% | 40.51B | |
-15.94% | 31.67B | |
+52.66% | 24.62B | |
-14.50% | 15.65B | |
-14.38% | 12.07B | |
-9.12% | 11.97B | |
-42.56% | 11.61B | |
+4.87% | 8.81B | |
-4.33% | 8.5B |
- Stock Market
- Equities
- A302440 Stock
- News SK bioscience Co.,Ltd.
- SK bioscience : GSK, SK Bioscience start late-stage trials of COVID-19 vaccine